论文部分内容阅读
目的探究瑞舒伐他汀联合奥美沙坦酯对老年高血压患者内皮功能及血压变异性的影响。方法 68例老年高血压患者,随机分为对照组和研究组,各34例。对照组予以奥美沙坦酯治疗,研究组在对照组基础上予以瑞舒伐他汀治疗。比较两组患者治疗前后舒张压变异性(DBPV)、收缩压变异性(SBPV)及内皮功能指标变化。结果治疗后研究组内皮素-1(ET-1)和一氧化氮(NO)指标分别为(71.6±6.2)ng/L、(59.2±5.0)μmol/L,对照组分别为(83.5±9.0)ng/L、(51.3±4.4)μmol/L;治疗后,两组患者内皮功能指标均优于治疗前,且研究组优于对照组(P<0.05)。治疗后,两组患者血压变异性均优于治疗前,且研究组明显优于对照组(P<0.05)。结论对老年高血压患者予以瑞舒伐他汀与奥美沙坦酯联合治疗,可显著降低患者血压变异性,有效改善内皮功能,在临床治疗中具有重要意义。
Objective To investigate the effect of rosuvastatin combined with olmesartan medoxomil on endothelial function and blood pressure variability in elderly patients with hypertension. Methods 68 cases of elderly hypertensive patients were randomly divided into control group and study group, 34 cases in each. The control group was treated with olmesartan medoxomil, and the study group was given rosuvastatin on the basis of the control group. The changes of diastolic pressure variability (DBPV), systolic blood pressure variability (SBPV) and endothelial function were compared between the two groups before and after treatment. Results After treatment, the indexes of ET-1 and NO were (71.6 ± 6.2) ng / L and (59.2 ± 5.0) μmol / L in the study group and 83.5 ± 9.0 (51.3 ± 4.4) μmol / L. After treatment, the endothelial function indexes in both groups were better than those before treatment, and the study group was better than the control group (P <0.05). After treatment, the blood pressure variability in both groups were better than before treatment, and the study group was significantly better than the control group (P <0.05). Conclusions Combination of rosuvastatin and olmesartan medoxomil in senile patients with hypertension can significantly reduce the variability of blood pressure and effectively improve endothelial function, which is of great significance in clinical treatment.